This study was conducted in accordance with the requirements of the clinical approval document (CFDA2013L01855). It was a randomized, controlled, open, multicenter, phase II / III clinical trial to evaluate the safety and efficacy of chlorogenic acid for injection in the treatment of recurrent grade IV glioblastoma ( GBM ) .
Trial objectives：
Evaluating Overall Survival (OS) of patients with Grade IV Glioblastoma (GBM) treated with Chlorogenic Acid for Injection.
Target group：
Patients with recurrent grade IV GBM who were ineffective after standard treatment ( surgery, radiotherapy and temozolomide chemotherapy ) and were diagnosed after screening examination.
Clinical Protocol Design：
Progress：
Central progress
|
Number of clinical centers
|
Center name
|
|
launch |
11 |
Beijing tiantan hospital. capital medical university； Harbin medical university cancer hospital； Chongqing cancer hospital； Union hospital tongji medical college huazhong university of science and technology； General hospital of ningxia medical university； Jiangsu province hospital； Tianjin huanhu hospital； Shenzhen second people's hospital； Xi 'an tangdu hospital； Sichuan provincial people's hospital； Peking union medical college hospital. |
Up to now, all the groups have been completed and entered the data cleaning stage.